Oryzon Genomics falling until 2.05-2.13?The recent capital increase may drag the stock price lower from current levels. Fib retracement 0.618 stops at 2.33 but indeed 2.125 (from back in Dec 2018) is a great support that ORY might want to test.
Next report date
Report period
Q1 2024
EPS estimate
−0.03EUR
Revenue estimate
—
−0.060EUR
−3.35 MEUR
50.76 M
About ORYZON GENOMICS, S.A.
Sector
Industry
CEO
Carlos Manuel Buesa Arjol
Website
Headquarters
Barcelona
Founded
2000
ISIN
ES0167733015
FIGI
BBG00JHW73D1
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0RDB is 1.990 EUR — it has decreased by 0.50% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ORYZON GENOMICS SA EUR0.05 stocks are traded under the ticker 0RDB.
ORYZON GENOMICS SA EUR0.05 is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
0RDB stock is 0.50% volatile and has beta coefficient of 0.34. Check out the list of the most volatile stocks — is ORYZON GENOMICS SA EUR0.05 there?
0RDB earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.04 EUR resulting in a 55.04% surprise. The estimated earnings for the next quarter are −0.05 EUR per share. See more details about ORYZON GENOMICS SA EUR0.05 earnings.
Yes, you can track ORYZON GENOMICS SA EUR0.05 financials in yearly and quarterly reports right on TradingView.
0RDB stock has risen by 0.49% compared to the previous week, the month change is a 14.50% rise, over the last year ORYZON GENOMICS SA EUR0.05 has showed a 5.24% decrease.
0RDB net income for the last quarter is −1.72 M EUR, while the quarter before that showed −1.06 M EUR of net income which accounts for −62.14% change. Track more ORYZON GENOMICS SA EUR0.05 financial stats to get the full picture.
Today ORYZON GENOMICS SA EUR0.05 has the market capitalization of 124.35 M, it has increased by 11.24% over the last week.
No, 0RDB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0RDB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORYZON GENOMICS SA EUR0.05 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ORYZON GENOMICS SA EUR0.05 technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ORYZON GENOMICS SA EUR0.05 stock shows the neutral signal. See more of ORYZON GENOMICS SA EUR0.05 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ORYZON GENOMICS SA EUR0.05 future price: according to them, 0RDB price has a max estimate of 12.00 EUR and a min estimate of 2.50 EUR. Read a more detailed ORYZON GENOMICS SA EUR0.05 forecast: see what analysts think of ORYZON GENOMICS SA EUR0.05 and suggest that you do with its stocks.